

Date : 05.11.2016

To,  
The Secretary,  
The B.S.E Limited  
Floor 25, P.J. Towers,  
Dalal Street,  
Mumbai. - 400 001

The Manager (Listing Department)  
The Ahmedabad Stock Exchange Ltd.,  
Kamadhenu Complex,  
Opp. Sahajanand College, Panjarapole,  
Ahmedabad

**Sub: Outcome of the Board Meeting**

Please find enclosed Outcome of the board meeting held on 05<sup>th</sup> November, 2016

This is for your information and record.

Thanking you

for TRIMURTHI LTD

  
*Arun Kumar Bhargadia*  
Arun Kumar Bhargadia  
Managing Director  
DIN: 00021024



**TRIMURTHI LIMITED**

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)  
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,  
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370  
Email : info@trimurthidrugs.com  
Website : www.trimurthidrugs.com  
CIN No : L67120TG1994PLC018956

Date: 05-11-2016

To,  
The Secretary,  
The B.S.E Limited  
Floor 25, P.J. Towers,  
Dalal Street,  
Mumbai. - 400 001

The Manager (Listing Department)  
The Ahmedabad Stock Exchange Ltd.,  
Kamadhenu Complex,  
Opp. Sahajanand College, Panjarapole,  
Ahmedabad

**Sub : Outcome of the Board meeting.**

The meeting of the Board of Directors of the company started at 4:30 pm today. The outcome of the meeting is under:

The Board has considered and approved the minutes of the previous board meeting.

The board has considered and approved the Un-audited Quarterly Results of the company for the quarter ended 30<sup>th</sup> September, 2016.

Mr. Ram swaroop Agarwal has tabled resignation letter before the board , the chairman has noted and the same and authorised Mr.Arun Kumar Bhangadia to search for Independent Director due to vacancy by such resignation with in a stipulated time of 90 days as per Provisions of the Companies Act,2013.

There being no other matter meeting of the board of directors concluded with the vote of thanks.

Thanking you  
for **TRIMURTHI LIMITED.**



**Arun Kumar Bhangadia**  
Managing Director  
DIN: 00021024  
HYDERABAD



**TRIMURTHI LIMITED**

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)  
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,  
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370  
Email : info@trimurthidrugs.com  
Website : www.trimurthidrugs.com  
CIN No : L67120TG1994PLC018956



# TRIMURTHI LIMITED

(Formerly Known as TRIMURTHI DRUGS & PHARMACEUTICALS LIMITED)  
CONSOLIDATED UNAUDITED QUARTERLY RESULTS FOR THE QUARTER ENDED SEPTEMBER, 2016



TRIMURTHI GROUP (Rs. In Lakhs)

PART-I STATEMENT OF CONSOLIDATED UNAUDITED RESULTS FOR QUARTER II AND THREE MONTHS ENDED 30/09/2016						
Particulars	3 Months ended 30-09-2016	Preceding 3 months ended 30-06-2016	Correspondin g 3 months ended 30-09-2015	Year to date figures for the current period ended 30-09-2016	Year to date figures for the previous year ended 30-09-2015	Year ended 31-03-2016
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
<b>1. Income From Operations</b>						
Net Sales / Income from Operations	188.66	284.12	120.73	472.78	245.87	470.83
Other Operating Income	16.09	12.34	22.64	28.44	46.40	100.76
<b>Total Operating Income(Net)</b>	<b>204.76</b>	<b>296.46</b>	<b>143.37</b>	<b>501.22</b>	<b>292.27</b>	<b>571.59</b>
<b>2. Expenditure</b>						
a. Consumption of Raw Material	Nil	Nil	Nil	Nil	Nil	Nil
b. Purchase of Traded Goods	181.12	289.16	115.36	470.28	224.67	411.89
c. (Increase)/Decrease in stock in trade and work in Progress	(17.99)	(18.27)	(10.03)	(36.25)	(9.17)	(0.64)
d. Employees Cost	13.30	12.83	12.71	26.12	24.17	60.43
e. Depreciation	2.72	3.26	6.98	5.99	15.79	35.08
f. Other Expenditure	10.51	11.69	9.74	22.21	19.39	44.67
<b>Total</b>	<b>189.66</b>	<b>298.68</b>	<b>134.77</b>	<b>488.34</b>	<b>274.85</b>	<b>551.43</b>
<b>Profit/ (Loss) from Operations before Other Income, Finance Cost &amp; Exceptional Items (2-1)</b>	<b>15.10</b>	<b>(2.22)</b>	<b>8.60</b>	<b>12.88</b>	<b>17.43</b>	<b>20.16</b>
4. Other Income	3.94	0.28	3.90	4.22	8.46	13.23
<b>Profit/ (Loss) from Ordinary Activities before Finance Cost &amp; Exceptional Items (3+4)</b>	<b>19.04</b>	<b>(1.94)</b>	<b>12.50</b>	<b>17.10</b>	<b>25.89</b>	<b>33.39</b>
6. Finance Cost	0.00	0.00	0.00	0.00	0.00	0.06
<b>Profit/ (Loss) from Ordinary activities after finance cost but before exceptional items (5+6)</b>	<b>19.04</b>	<b>(1.94)</b>	<b>12.50</b>	<b>17.10</b>	<b>25.89</b>	<b>33.33</b>
8. Exceptional Items	Nil	Nil	Nil	Nil	Nil	Nil
<b>Profit/ (Loss) from Ordinary activities before Prior period items and tax (7+8)</b>	<b>19.04</b>	<b>(1.94)</b>	<b>12.50</b>	<b>17.10</b>	<b>25.89</b>	<b>33.33</b>
10. Prior period Items	0.00	0.00	Nil	0.00	Nil	9.17
<b>Profit/ (Loss) from Ordinary activities before tax (7+8)</b>	<b>19.04</b>	<b>(1.94)</b>	<b>12.50</b>	<b>17.10</b>	<b>25.89</b>	<b>24.16</b>
11. Tax Expense (Including Deferred Tax)	4.85	1.12	4.31	5.97	7.92	11.20
<b>Net Profit/ (Loss) from Ordinary activities after Tax (9+10)</b>	<b>14.18</b>	<b>(3.05)</b>	<b>8.20</b>	<b>11.13</b>	<b>17.97</b>	<b>12.96</b>
13. Extraordinary Items(Net Of Tax Expenses)	Nil	Nil	Nil	Nil	Nil	Nil
<b>Net Profit/ (Loss) for the period</b>	<b>14.18</b>	<b>(3.05)</b>	<b>8.20</b>	<b>11.13</b>	<b>17.97</b>	<b>12.96</b>
15. Share of Profit/(loss) Of Associates	-NA-	-NA-	-NA-	-NA-	-NA-	-NA-
16. Minority Interest	4.34	1.03	1.66	5.37	3.44	3.04
<b>Net Profit/ (Loss) after taxes, Minority Interest and Share Of Profit/(Loss) of Associates (13+14+15)</b>	<b>9.84</b>	<b>(4.08)</b>	<b>6.54</b>	<b>5.76</b>	<b>14.53</b>	<b>9.91</b>
18. Paid-up Equity Share Capital (Face Value of Rs.10/- each)	810.00	810.00	810.00	810.00	810.00	810.00
19. Reserves excluding revaluation reserves as per balance sheet of previous accounting year	345.11	345.11	332.90	345.11	332.90	345.11
<b>20. Earnings Per Share (EPS)</b>						
i. Basic & Diluted before extraordinary items (not annualised)	0.12	(0.05)	0.08	0.07	0.10	0.12
ii. Basic & Diluted after extraordinary items (not annualised)	0.12	(0.05)	0.08	0.07	0.10	0.12



## TRIMURTHI LIMITED

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)  
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,  
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370  
Email : info@trimurthidrugs.com  
Website : www.trimurthidrugs.com  
CIN No : L67120TG1994PLC018956





## TRIMURTHI LIMITED

(Formerly Known as TRIMURTHI DRUGS & PHARMACEUTICALS LIMITED)  
CONSOLIDATED UNAUDITED QUARTERLY RESULTS FOR THE QUARTER ENDED SEPTEMBER 2016

TRIMURTHI  
GROUP

### PART-II

#### Select Information for Quarter II and Three months Ended 30/09/2016

Particulars	3 Months ended 30-09-2016	Preceding 3 months ended 30-06-2016	Correspondin g 3 months ended 30-09-2015	Year to date figures for the current period ended 30-09-2016	Year to date figures for the previous year ended 30-09-2015	Year ended 31-03-2016
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
<b>A. Particulars Of Share Holding</b>						
1. Public Share Holding						
- Number of Shares	2849600	2849600	2849600	2849600	2849600	2849600
- Percentage of shareholding	35.18%	35.18%	35.18%	35.18%	35.18%	35.18%
2. Promoters and promoter group shareholding						
a. Pledged / encumbered						
- No of Equity Shares	Nil	Nil	Nil	Nil	Nil	Nil
- Percentage of Shares (of the shareholding of promoter and promoter group)	Nil	Nil	Nil	Nil	Nil	Nil
- Percentage of Shares (of the total share capital of the company)	Nil	Nil	Nil	Nil	Nil	Nil
b. Non encumbered						
- No of Equity Shares	5250400	5250400	5250400	5250400	5250400	5250400
- Percentage of Shares (of the shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
- Percentage of Shares (of the total share capital of the company)	64.82%	64.82%	64.82%	64.82%	64.82%	64.82%
<b>3 Months Ended ( 30/09/2016)</b>						
<b>B. Investor Complaints</b>						
Pending at the beginning of the quarter				-NIL-		
Received during the quarter				-NIL-		
Disposed during the quarter				-NIL-		
Remaining unsolved during the quarter				-NIL-		

#### Segment Reporting

Particulars	Quarters ended			Period ended		Year ended
	30/09/2016 Unaudited	30/06/2016 Unaudited	30/09/2015 Unaudited	30/09/2016 Unaudited	30/09/2015 Unaudited	31/03/2016 Audited
<b>1. Segment Revenue</b>						
a. Pharma Business	150.90	128.55	122.68	279.45	250.00	478.60
b. Financial Services	14.09	10.12	20.69	24.21	42.28	93.00
c. Investments	(0.28)	0.28	3.90	0.00	8.46	13.23
d. Foods	0.00	0.00	0.00	0.00	0.00	0.00
e. Trading in Shares	39.76	157.80	0.00	197.56	0.00	0.00
<b>Total</b>	<b>204.48</b>	<b>296.74</b>	<b>147.27</b>	<b>501.22</b>	<b>300.74</b>	<b>584.82</b>
<b>Less: Inter Segment Revenue</b>	<b>-Nil-</b>	<b>-Nil-</b>	<b>-Nil-</b>	<b>-Nil-</b>	<b>-Nil-</b>	<b>-Nil-</b>
<b>Net Sales/ Income From Operations</b>	<b>204.48</b>	<b>296.74</b>	<b>147.27</b>	<b>501.22</b>	<b>300.74</b>	<b>584.82</b>
<b>2. Segment Profits ( Before tax &amp; Interest From Each Segment)</b>						
a. Pharma Business	20.59	2.77	7.34	23.36	13.32	19.26
b. Financial Services	23.40	(10.60)	1.93	12.81	5.18	2.41
c. Investments	(2.64)	2.26	3.22	(0.38)	7.39	12.94
d. Foods	1.69	0.00	0.00	1.69	0.00	0.00
e. Trading in Shares	(20.38)	0.00	0.00	(20.38)	0.00	0.00
<b>Total</b>	<b>22.67</b>	<b>(5.57)</b>	<b>12.50</b>	<b>17.10</b>	<b>25.89</b>	<b>34.60</b>
<b>Less:</b>						
i. Interest	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
ii. Other Un-allocable expenses net off	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
iii. Un-allocable Income	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
<b>Total Profit Before Tax</b>	<b>22.67</b>	<b>(5.57)</b>	<b>12.50</b>	<b>17.10</b>	<b>25.89</b>	<b>34.60</b>
<b>3. Capital Employed</b>						
a. Pharma Business	86.00	75.05	85.66	86.00	85.66	61.18
b. Financial Services	471.51	331.93	1039.60	471.51	1039.60	910.43
c. Investments	463.77	585.88	75.58	463.77	75.58	169.89
d. Foods	125.17	118.39	0.00	125.17	0.00	64.33
e. Trading in Shares	51.18	91.53	0.00	51.18	0.00	0.00
<b>Total</b>	<b>1197.63</b>	<b>1202.78</b>	<b>1200.85</b>	<b>1197.63</b>	<b>1200.85</b>	<b>1205.83</b>

#### Notes:

- The above results have been taken on record by the board of directors of the company at their meeting held on 05-11-2016
- The financial results for the quarter ended 30-09-2016 have been reviewed by the statutory auditors in pursuance of listing agreement.
- In segment reporting common assets that are used interchangeable not allocated to the individual segment above.

Place : Hyderabad,  
Date : 5th November, 2016.

### TRIMURTHI LIMITED

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)  
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,  
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370  
Email : info@trimurthidrugs.com  
Website : www.trimurthidrugs.com  
CIN No : L67120TG1994PLC018956







**TRIMURTHI LIMITED**  
(Formerly Known as TRIMURTHI DRUGS & PHARMACEUTICALS LIMITED)  
**CONSOLIDATED ASSETS AND LIABILITIES FOR THE YEAR ENDED ON 30-09-2016**

**TRIMURTHI GROUP**

(Rupees in Lacs)

Particulars	As at 30-09-2016	As at 31-03-2016
<b>A. EQUITY AND LIABILITIES</b>		
<b>1. Share Holders' Funds:</b>		
(a) Share Capital	810.00	810.00
(b) Reserves and Surplus	350.22	344.46
(c) Money received against warrants		
<b>Sub-Total Share Holders' Funds</b>	<b>1160.22</b>	<b>1155.11</b>
<b>2. Share Application pending for Allotment</b>	-Nil-	-Nil-
<b>3. Minority Interest*</b>	37.41	50.72
<b>4. Non Current Liabilities:</b>		
(a) Long Term Borrowings	-Nil-	-Nil-
(b) Deferred Tax Liabilities (Net)	2.48	2.38
(c) Other Long Term Liabilities	-Nil-	-Nil-
(d) Long Term Provisions	-Nil-	-Nil-
<b>Sub-Total Non Current Liabilities</b>	<b>2.48</b>	<b>2.38</b>
<b>5. Current Liabilities</b>		
(a) Short Term Borrowings	-Nil-	-Nil-
(b) Trade Payables	71.95	36.98
(c) Other Current Liabilities	36.14	11.18
(d) Short Term Provisions	5.87	17.14
(e) Inter Division	-Nil-	-Nil-
<b>Sub-Total Current Liabilities</b>	<b>113.96</b>	<b>65.29</b>
<b>TOTAL EQUITY &amp; LIABILITIES</b>	<b>1314.07</b>	<b>1273.51</b>
<b>B. ASSETS</b>		
<b>1. Non-Current Assets:</b>		
(a) Fixed Assets	207.18	96.11
(b) Non-Current Investments	15.00	5.00
(c) Deferred Tax Assets (Net)	-Nil-	-Nil-
(d) Long Term Loans and Advances	20.90	20.90
(e) Other Non-Current Assets	5.27	7.61
<b>Sub-Total Non Current Assets</b>	<b>248.35</b>	<b>129.62</b>
<b>2. Current Assets:</b>		
(a) Current Investments	193.19	164.16
(b) Inventories	81.91	45.65
(c) Trade Receivables	89.33	53.24
(d) Cash & Cash Equivalents	50.46	143.39
(e) Short Term Loans and Advances	643.92	721.69
(f) Other Current Assets	6.91	15.76
<b>Sub-Total Current Assets</b>	<b>1065.72</b>	<b>1143.89</b>
<b>TOTAL ASSETS</b>	<b>1314.07</b>	<b>1273.51</b>

**TRIMURTHI LIMITED**

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)  
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,  
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370  
Email : info@trimurthidrugs.com  
Website : www.trimurthidrugs.com  
CIN No : L67120TG1994PLC018956





**TRIMURTHI LIMITED**  
(Formerly Known as TRIMURTHI DRUGS & PHARMACEUTICALS LIMITED)  
STANDALONE UNAUDITED QUARTERLY RESULTS FOR THE QUARTER ENDED SEPTEMBER 2016.

**TRIMURTHI**  
GROUP (Rs. In Lakhs)

PART-I STATEMENT OF STANDALONE UNAUDITED RESULTS FOR QUARTER II AND THREE MONTHS ENDED 30-09-2016						
Particulars	3 Months ended 30-09-2016	Preceeding 3 months ended 30-06-2016	Corresponding 3 months ended 30-09-2015	Year to date figures for the current period ended 30-09-2016	Year to date figures for the previous year ended 30-09-2015	Year ended 31-03-2016
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
<b>1. Income From Operations</b>						
Net Sales / Income from Operations	39.76	157.80	0.00	197.56	0.00	0.00
Other Operating Income	14.09	10.12	20.65	24.21	41.71	93.00
<b>Total Operating Income(Net)</b>	<b>53.85</b>	<b>167.91</b>	<b>20.65</b>	<b>221.77</b>	<b>41.71</b>	<b>93.00</b>
<b>2. Expenditure</b>						
a. Consumption of Raw Material	Nil	Nil	Nil	Nil	Nil	Nil
b. Purchase of Traded Goods/Shares	63.38	173.41	0.00	236.79	0.00	0.00
c. (Increase)/Decrease in stock in trade and work in Progress	(24.81)	(16.46)	0.00	(41.26)	0.00	0.00
d. Employees Cost	5.43	5.28	5.67	10.71	9.81	23.94
e. Rent	0.75	0.75	0.30	1.50	0.50	1.65
f. Depreciation	2.35	2.89	6.12	5.25	14.57	33.60
g. Other Expenditure	5.52	7.46	4.38	12.99	10.35	27.78
<b>Total</b>	<b>52.63</b>	<b>173.34</b>	<b>16.47</b>	<b>225.97</b>	<b>35.22</b>	<b>86.96</b>
<b>3. Profit/ (Loss) from Operations before Other Income, Finance Cost &amp; Exceptional Items (2-1)</b>	<b>1.22</b>	<b>(5.42)</b>	<b>4.18</b>	<b>(4.20)</b>	<b>6.50</b>	<b>6.03</b>
4. Other Income	2.28	(0.05)	3.79	2.23	8.36	7.52
<b>5. Profit/ (Loss) from Ordinary Activities before Finance Cost &amp; Exceptional Items (3+4)</b>	<b>3.50</b>	<b>(5.48)</b>	<b>7.97</b>	<b>(1.97)</b>	<b>14.85</b>	<b>13.56</b>
6. Finance Cost	0.00	0.00	0.00	0.00	0.00	0.00
<b>7. Profit/ (Loss) from Ordinary activities after finance cost but before exceptional items (5+6)</b>	<b>3.50</b>	<b>(5.48)</b>	<b>7.97</b>	<b>(1.97)</b>	<b>14.85</b>	<b>13.56</b>
8. Exceptional Items	Nil	Nil	Nil	Nil	Nil	Nil
<b>9. Profit/ (Loss) from Ordinary activities before tax (7+8)</b>	<b>3.50</b>	<b>(5.48)</b>	<b>7.97</b>	<b>(1.97)</b>	<b>14.85</b>	<b>13.56</b>
10. Tax Expense (Including Deferred Tax)	0.14	(0.03)	2.12	0.11	3.79	3.73
<b>11. Net Profit/ (Loss) from Ordinary activities after Tax (9+10)</b>	<b>3.36</b>	<b>(5.45)</b>	<b>5.86</b>	<b>(2.08)</b>	<b>11.06</b>	<b>9.82</b>
12. Extraordinary Items(Net Of Tax Expenses)	Nil	Nil	Nil	Nil	Nil	Nil
<b>13. Net Profit/ (Loss) for the period (11+12)</b>	<b>3.36</b>	<b>(5.45)</b>	<b>5.86</b>	<b>(2.08)</b>	<b>11.06</b>	<b>9.82</b>
14. Share Of Profit/(loss) Of Associates	-NA-	-NA-	-NA-	-NA-	-NA-	-NA-
15. Minority Interest	-NA-	-NA-	-NA-	-NA-	-NA-	-NA-
<b>16. Net Profit/ (Loss) after taxes, Minority Interest and Share Of Profit/(Loss) of Associates (13+14+15)</b>	<b>3.36</b>	<b>(5.45)</b>	<b>5.86</b>	<b>(2.08)</b>	<b>11.06</b>	<b>9.82</b>
17. Paid-up Equity Share Capital (Face Value of Rs.10/- each)	810.00	810.00	810.00	810.00	810.00	810.00
18. Reserves excluding revaluation reserves, as per balance sheet of previous accounting year	334.09	334.09	324.27	334.09	324.27	334.09
<b>19. Earnings Per Share (EPS)</b>						
<b>i. Basic &amp; Diluted before extraordinary items (not annualised)</b>	<b>0.04</b>	<b>(0.07)</b>	<b>0.07</b>	<b>(0.03)</b>	<b>0.14</b>	<b>0.12</b>
<b>ii. Basic &amp; Diluted after extraordinary items (not annualised)</b>	<b>0.04</b>	<b>(0.07)</b>	<b>0.07</b>	<b>(0.03)</b>	<b>0.14</b>	<b>0.12</b>



**TRIMURTHI LIMITED**

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)  
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,  
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370  
Email : info@trimurthidrugs.com  
Website : www.trimurthidrugs.com  
CIN No : L67120TG1994PLC018956







## TRIMURTHI LIMITED

(Formerly Known as TRIMURTHI DRUGS & PHARMACEUTICALS LIMITED)  
STANDALONE UNAUDITED QUARTERLY RESULTS FOR THE QUARTER ENDED SEPTEMBER 2016.

**TRIMURTHI**  
GROUP

PART-II

SELECT INFORMATION FOR QUARTER I AND THREE MONTHS ENDED 30-09-2016

Particulars	3 Months ended 30-09-2016	Preceding 3 months ended 30-06-2016	Corresponding 3 months ended 30-09-2015	Year to date figures for the current period ended 30-09-2016	Year to date figures for the previous year ended 30-09-2015	Year ended 31-03-2016
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
<b>A. Particulars Of Share Holding</b>						
1. Public Share Holding						
- Number of Shares	2849600	2849600	2849600	2849600	2849600	2849600
- Percentage of shareholding	35.18%	35.18%	35.18%	35.18%	35.18%	35.18%
2. Promoters and promoter group shareholding						
a. Pledged / encumbered						
- No of Equity Shares	Nil	Nil	Nil	Nil	Nil	Nil
- Percentage of Shares (of the shareholding of promoter and promoter group)	Nil	Nil	Nil	Nil	Nil	Nil
- Percentage of Shares (of the total share capital of the company)	Nil	Nil	Nil	Nil	Nil	Nil
b. Non encumbered						
- No of Equity Shares	5250400	5250400	5250400	5250400	5250400	5250400
- Percentage of Shares (of the shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
- Percentage of Shares (of the total share capital of the company)	64.82%	64.82%	64.82%	64.82%	64.82%	64.82%

Particulars	3 Months Ended ( 30/09/2016)	
<b>B. Investor Complaints</b>		
Pending at the beginning of the quarter		-NIL-
Received during the quarter		-NIL-
Disposed during the quarter		-NIL-
Remaining unsolved during the quarter		-NIL-

### Segment Reporting

Particulars	Quarters ended			Period ended		Year ended
	30/09/2016 Unaudited	30/06/2016 Unaudited	30/09/2015 Unaudited	30/09/2016 Unaudited	30/09/2015 Unaudited	31/03/2016 Audited
<b>1. Segment Revenue</b>						
a. Pharma Business	0.00	0.00	0.00	0.00	0.00	0.00
b. Financial Services	14.02	10.19	20.65	24.21	41.71	93.00
c. Investments	0.08	(0.08)	3.79	0.00	8.36	7.52
d. Trading in Shares	39.76	157.80	0.00	197.56	0.00	0.00
<b>Total</b>	<b>53.86</b>	<b>167.91</b>	<b>24.44</b>	<b>221.77</b>	<b>50.07</b>	<b>100.52</b>
Less: Inter Segment Revenue	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
<b>Net Sales/ Income From Operations</b>	<b>53.86</b>	<b>167.91</b>	<b>24.44</b>	<b>221.77</b>	<b>50.07</b>	<b>100.52</b>
<b>2. Segment Profits ( Before tax &amp; Interest From Each Segment)</b>						
a. Pharma Business	0.00	0.00	0.00	0.00	0.00	0.00
b. Financial Services	6.93	2.05	4.85	8.99	7.57	6.32
c. Investments	2.36	(0.13)	3.12	2.23	7.28	7.24
d. Trading in Shares	(5.79)	(7.40)	0.00	(13.19)	0.00	0.00
<b>Total</b>	<b>3.50</b>	<b>(5.48)</b>	<b>7.97</b>	<b>(1.97)</b>	<b>14.85</b>	<b>13.56</b>
Less:						
i. Interest	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
ii. Other Un-allocable expenses net off	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
iii. Un-allocable Income	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
<b>Total Profit Before Tax</b>	<b>3.50</b>	<b>(5.48)</b>	<b>7.97</b>	<b>(1.97)</b>	<b>14.85</b>	<b>13.56</b>
<b>3. Capital Employed</b>						
a. Pharma Business	0.88	1.36	3.48	2.24	13.82	-Nil-
b. Financial Services	190.48	281.03	51.88	471.51	914.13	842.40
c. Investments	(212.74)	572.43	(44.51)	359.69	207.38	301.69
d. Trading in Shares	24.75	283.82	0.00	308.57	0.00	0.00
<b>Total</b>	<b>3.36</b>	<b>1138.64</b>	<b>10.85</b>	<b>1142.01</b>	<b>1135.33</b>	<b>1144.09</b>

### Notes:

- The above results have been taken on record by the board of directors of the company at their meeting held on 05-11-2016
  - The financial results for the quarter ended 30-09-2016 have been reviewed by the statutory auditors in pursuance of listing agreement.
  - In segment reporting common assets that are used interchangeable not allocated to the individual segment above.
- Place : Hyderabad,  
Date : 05th November, 2016.

### TRIMURTHI LIMITED

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)  
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,  
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370  
Email : info@trimurthidrugs.com  
Website : www.trimurthidrugs.com  
CIN No : L67120TG1994PLC018956







**TRIMURTHI**  
GROUP

**TRIMURTHI LIMITED**  
(Formerly Known as TRIMURTHI DRUGS & PHARMACEUTICALS LIMITED)  
STANDALONE ASSETS AND LIABILITIES FOR THE QUARTER YEAR ENDED ON 30-09-2016

(Rupees in Lacs)

Particulars	As at 30/09/2016	As at 31/03/2016
<b>A. EQUITY AND LIABILITIES</b>		
<b>1. Share Holders' Funds:</b>		
(a) Share Capital	810.00	810.00
(b) Reserves and Surplus	332.01	334.09
(c) Money received against warrants	0.00	0.00
<b>Sub-Total Share Holders' Funds</b>	<b>1142.01</b>	<b>1144.09</b>
<b>2. Share Application pending for Allotment</b>	-Nil-	-Nil-
<b>3. Minority Interest*</b>	-Nil-	-Nil-
<b>4. Non Current Liabilities:</b>		
(a) Long Term Borrowings	-Nil-	-Nil-
(b) Deferred Tax Liabilities (Net)	2.45	2.35
(c) Other Long Term Liabilities	-Nil-	-Nil-
(d) Long Term Provisions	-Nil-	-Nil-
<b>Sub-Total Non Current Liabilities</b>	<b>2.45</b>	<b>2.35</b>
<b>4. Current Liabilities</b>		
(a) Short Term Borrowings	-Nil-	-Nil-
(b) Trade Payables	15.20	-Nil-
(c) Other Current Liabilities	6.34	7.55
(d) Short Term Provisions	-Nil-	9.66
(e) Inter Division	-Nil-	-Nil-
<b>Sub-Total Current Liabilities</b>	<b>21.55</b>	<b>17.21</b>
<b>TOTAL EQUITY &amp; LIABILITIES</b>	<b>1166.01</b>	<b>1163.64</b>
<b>B. ASSETS</b>		
<b>1. Non-Current Assets:</b>		
(a) Fixed Assets	64.43	63.61
(b) Non-Current Investments	166.50	136.80
(c) Deferred Tax Assets (Net)	-Nil-	-Nil-
(d) Long Term Loans and Advances	20.90	20.90
(e) Other Non-Current Assets	2.24	2.24
<b>Sub-Total Non Current Assets</b>	<b>254.07</b>	<b>223.55</b>
<b>2. Current Assets:</b>		
(a) Current Investments	193.19	164.16
(b) Inventories	41.26	-Nil-
(c) Trade Receivables	-Nil-	0.73
(d) Cash & Cash Equivalents	30.47	44.42
(e) Short Term Loans and Advances	642.42	719.57
(f) Other Current Liabilities	4.59	11.21
<b>Sub-Total Current Assets</b>	<b>911.93</b>	<b>940.10</b>
<b>TOTAL ASSETS</b>	<b>1166.01</b>	<b>1163.64</b>

**TRIMURTHI LIMITED**

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)  
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,  
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370  
Email : info@trimurthidrugs.com  
Website : www.trimurthidrugs.com  
CIN No : L67120TG1994PLC018956







# K. Venkateswara Rao & Associates

## Chartered Accountants

Door No. 3-5-907/2, Flat No.402, Mahavir Lok, Himayathnagar Main Road, Hyderabad - 500 029.  
e-mail: v\_kommineni@yahoo.com

### Annexure V to Clause 41

Review Report to:

The Board of Directors,  
Trimurthi Limited  
Hyderabad.

We have reviewed the accompanying statement of unaudited financial results of **TRIMURTHI LIMITED** for the period ending **30<sup>th</sup> September, 2016**. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/ committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, *Engagements to Review Financial Statements* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards (Note 1) and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For K.VENKATESWARA RAO & ASSOCIATES  
CHARTERED ACCOUNTANTS  
FRN : 006374S

PLACE: HYDERABAD  
DATE: 05.11.2016

K.VENKATESWARA RAO  
PROPRIETOR  
M.No. 20027305

**Note 1.** The Accounting Standards notified pursuant to the Companies (Accounting Standards) Rules, 2006 and/or Accounting Standards issued by Institute of Chartered Accountants of India.